NasdaqGS:TEMLife Sciences
Tempus AI (TEM) Valuation Check After Daiichi Sankyo Oncology Collaboration Announcement
Tempus AI’s oncology collaboration puts its AI platform in focus
Tempus AI (TEM) drew fresh attention after announcing a collaboration with Daiichi Sankyo to apply its PRISM2 multimodal foundation model and real world oncology data to a novel antibody drug conjugate program.
See our latest analysis for Tempus AI.
The Daiichi Sankyo collaboration arrives after a volatile stretch for the stock, with a 1-day share price return of 6.7% lifting Tempus AI to US$45.22. However, a weaker 90-day share...